Cardiovascular Drugs and Therapy

, Volume 24, Issue 1, pp 61-70

First online:

Antiplatelet and Anticoagulant Therapies in Acute Coronary Syndromes

  • Elias B. HannaAffiliated withCardiology Department, Oklahoma University Email author 
  • , David Luke GlancyAffiliated withCardiology Department, Louisiana State University
  • , Jorge F. SaucedoAffiliated withCardiology Department, Oklahoma University

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


The combination of aspirin and clopidogrel is the mainstay antiplatelet therapy for acute coronary syndromes (ACS). However, the dosing of aspirin, the dosing of clopidogrel, the timing of clopidogrel initiation as well as the duration of clopidogrel therapy remain controversial matters. Clopidogrel resistance is an emerging concept with potential clinical implications. In the era of clopidogrel and bivalirudin, the role of glycoprotein IIb/IIIa antagonists is being challenged, yet they are still indicated in a select high-risk population. Concerning anticoagulant use in ACS, newer agents, bivalirudin and fondaparinux, have improved outcomes in comparison to heparin in patients managed with an invasive or conservative strategy, respectively. Combining multiple antiplatelet agents and an anticoagulant is the standard of care for ACS.

Key words

Acute coronary syndrome Myocardial infarction Antiplatelet Anticoagulant Aspirin Clopidogrel Prasugrel Ticagrelor Glycoprotein IIb/IIIa antagonist Unfractionated heparin Enoxaparin Bivalirudin Fondaparinux